O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Marc Bourlière ,Lawrence Serfaty ,Isabelle Rosa ,Dominique Guyader ,Christophe Hézode ,Anthony Tran ,Jean Didier Grangé ,Nathalie Ganne‐Carrié ,P Attali ,Josefina Molina ,Noelle Pouget ,H Fontaine ,Pascaline Rabiéga ,J.-P Bronowicki ,Vincent Leroy ,Y Bacq ,Magali Bouvier–Alias ,Patrick Marcellin ,Fabrice Carrat ,Xavier Causse ,Inga Bertucci ,Fabien Zoulim ,Ghassan Riachi ,Maurice Picon ,Yves Benhamou

doi:10.1016/s0168-8278(15)30131-8

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Marc Bourlière , Lawrence Serfaty + Show 23 more

https://doi.org/10.1016/s0168-8278(15)30131-8

Copy DOI

#HBeAg Negative CHB Patients #Ide Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Full Text